13,589
Total Claims
$1.8M
Drug Cost
1,395
Beneficiaries
$1,290
Cost/Patient
Peer Comparison vs. 4,479 Interventional Cardiology providers
+22%
Cost per patient vs peers
$1,290 vs $1,054 avg
+8%
Brand preference vs peers
14.2% vs 13.1% avg
Brand vs Generic
86% generic
Brand: 1,936 claims · $1.6M
Generic: 11,653 claims · $218K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 669 | $652K |
| Sacubitril/Valsartan | 242 | $284K |
| Rivaroxaban | 258 | $224K |
| Dapagliflozin Propanediol | 107 | $97K |
| Evolocumab | 120 | $89K |
| Empagliflozin | 56 | $58K |
| Ticagrelor | 88 | $58K |
| Alirocumab | 51 | $42K |
| Ranolazine | 140 | $19K |
| Icosapent Ethyl | 41 | $17K |
| Evolocumab | 27 | $16K |
| Metoprolol Succinate | 997 | $16K |
| Rosuvastatin Calcium | 790 | $13K |
| Atorvastatin Calcium | 837 | $11K |
| Amlodipine Besylate | 1,035 | $7,542 |
Prescribing Profile
84
Unique Drugs
$1.3M
Patient Profile
74
Avg Age
54%
Female
1.47
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About